Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis.
Many approved cancer drugs rest on trials with quality concerns or modest benefits, signaling need for clearer evidence standards in oncology approvals.
This systematic meta-research study characterizing all pivotal phase 3 RCTs supporting FDA anticancer drug approvals from 2018–2025 reveals substantial heterogeneity in trial quality and clinical benefit magnitude, with meaningful numbers of approvals resting on trials with high risk of bias or modest clinical effect sizes. The findings have important implications for oncology evidence standards, with direct relevance to the reliability of evidence for drugs currently in clinical use.
What the study was
- Study design
- Cross-sectional systematic analysis (meta-research)
- Population
- Pivotal phase 3 RCTs supporting FDA approval of new anticancer drugs 2018–2025
- Category
- Other
- Maturity
- Validated
- Journal
- European journal of cancer (Oxford, England : 1990)
Why it surfaced
Systematic characterization of evidence quality for FDA-approved anticancer drugs identifies systemic limitations in the evidence base; sentinel unsolicited find with broad oncology and regulatory policy relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.